
News|Articles|November 2, 2012
FDA: Pradaxa bleeding no higher than warfarin
Bleeding rates associated with new use of dabigatran (Pradaxa, Boehringer Ingelheim) do not appear to be higher than bleeding rates associated with new use of warfarin, according to an FDA safety review of post-market reports of serious bleeding events.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
7 things you need to know about the PBM reforms signed into law this week
2
Cancer survival fell and deaths rose during first two years of COVID-19
3
PBM reform. It has finally happened
4
TrumpRx launches; some experts question its long-term value
5

























